MedTrace Logo

The Individually Marked Panretinal lasEr phoTokoagUlation for Proliferative Diabetic Retinopathy Study - DETECT

NCT02157350 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2019-01-25

No results posted yet for this study

Summary

The purpose of this study is to determine the threshold level of proliferative diabetic retinopathy progression and regression after standard panretinal photocoagulation. Predictors of progression and regression will be identified which will include retinal vessel geometry (caliber, fractals and tortuosity), retinal vessel oxygen saturation and retinal areas of non-perfusion.

Conditions

  • Proliferative Diabetic Retinopathy

Interventions

PROCEDURE

Panretinal laser photocoagulation

Panretinal photocoagulation. Laser energy is given to the retina in two sittings, carefully avoiding the macular. The energy are placed 2 to 3 disc diameters away from the macula and the disc outside the arcades and extended peripherally upto the equator and beyond.

Sponsors & Collaborators

  • University of Southern Denmark

    collaborator OTHER

  • Moorfields Eye Hospital NHS Foundation Trust

    collaborator OTHER

  • National University of Singapore

    collaborator OTHER

  • Yamagata University

    collaborator OTHER

  • Odense University Hospital

    lead OTHER

Principal Investigators

  • Thomas L Torp, MD · Research Unit of Ophthalmology, University of Southern Denmark

  • Joakob Grauslund, DMSci, PhD · Research Unit of Ophthalmology, University of Southern Denmark

  • Tundo Peto, PhD,FHCO · NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS

  • Tien Y Wong, PhD · Department of Ophthalmology National University of Singapore

  • Ryo Kawasaki, PhD · Department of Public Health Ophthalmology, Yamagata

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-31
Primary Completion
2017-09-30
Completion
2017-09-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02157350 on ClinicalTrials.gov